@2024 - All Right Reserved.

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...

or on the link below. ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid ...

RFH Healthcare Managing Director Maxwel Okoth addresses a past press breifing. [File, Standard] RFH Healthcare has announced a medical milestone with the successful administration of Lutetium therapy ...

TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. This is an ASCO Meeting Abstract from the ...

BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy (Lu ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 Ra) ...

Dr. Rohan Garje reviews the latest rapid recommendation update for the ASCO guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC). He reviews what prompted ...